Tags: Biogen


ADDF Statement on Biogen and Eisai Discontinuing Trials of Aducanumab

Pharmaceuticals company Biogen and its partner Eisai announced that they will cease clinical trials for aducanumab after it was indicated the trials were unlikely to succeed.


Does Verubecestat Signal the End of the Amyloid Hypothesis?

Merck announces the end of another anti-amyloid drug trial, calling in to question the amyloid hypothesis and the fate of other anti-amyloid drugs.


What Does the Failure of Solanezumab Mean?

Eli Lilly announced that its Alzheimer's drug solanezumab failed in its last phase 3 clinical trial. Howard Fillit, MD, discusses what this means, and where we go from here.


ADDF-Funded PET Imaging Makes Clinical Trial Success Possible

A treatment has reduced beta-amyloid plaques in the brains of patients with Alzheimer’s disease.